A mini-planet orbiting in the frigid outer reaches of the solar system has a Saturn-like ring of dust and debris that defies the rules of physics, a new study has revealed. Space.com reports: The planet in question is called Quaoar and it's the seventh largest of the known dwarf planets of which Pluto is the king. Discovered in 2002 and about 697 miles wide (1,121 kilometers), Quaoar is one of the so-called trans-Neptunian objects, small planets orbiting beyond the solar system's outermost planet Neptune. Residing in the Kuiper Belt, the doughnut-shaped ring of rocky and icy debris in the outer solar system, Quaoar is a proud owner of its own moon, the 100-mile-wide (160 km) Weywot. And a recent observation campaign revealed that it also has a ring of material in its orbit. [...]

Quaoar's ring is at a very unusual distance from its parent body. In fact, before astronomers discovered Quaoar's ring in observations from several telescopes conducted between 2018 and 2021, they had thought that it was impossible for a ring to exist at such a distance. With a radius of about 2,420 miles (3,885 km) from Quaoar's center, the ring is too far away from the dwarf planet that its gravity should no longer be able to keep the material dispersed. Instead, it should coalesce under its own gravity and form another moon, just like Weywot. By not having done that, the ring has breached what astronomers call the Roche limit, the first known ring around a celestial body to have done so. [...] Now astronomers have to either rethink the Roche limit or come up with another explanation for the existence of Quaoar's ring. The study was published in the journal Nature.

An anonymous reader quotes a report from The Guardian: Scientists working on an experimental anti-ageing therapy claim to have broken a record by extending the lifespan of a lab rat called Sima. Named after the Hindi word for "limit" or "boundary", Sima is the last remaining survivor from a group of rodents that received infusions of blood plasma taken from young animals to see if the treatment prolonged their lives. Sima, who was born on February 28, 2019, has lived for 47 months, surpassing the 45.5 months believed to be the oldest age recorded in scientific literature for a female Sprague-Dawley rat, the researchers say. So far, Sima has outlived her closest rival in the study by nearly six months. "We have the oldest living female Sprague Dawley rat," said Dr Harold Katcher, a former biology professor at the University of Maryland, now chief scientific officer at Yuvan Research, a California-based startup.

Researchers have rushed to produce and trial therapies based on young blood plasma after numerous experiments found that infusions could reinvigorate aging organs and tissues. But while studies have found benefits for rodents, there is no evidence to date that the somewhat vampiric approach to youthfulness will help humans dodge the passage of time, despite the best wishes of Silicon Valley. The results from Katcher's latest study will be written up when Sima dies, but data gathered so far suggests that eight rats that received placebo infusions of saline lived for 34 to 38 months, while eight that received a purified and concentrated form of blood plasma, called E5, lived for 38 to 47 months. They also had improved grip strength. Rats normally live for two to three years, though a contender for the oldest ever is a brown rat that survived on a restricted calorie diet for 4.6 years.

A patent filing on the potential therapy describes how plasma from young mammals is purified and concentrated before use. Some components, such as platelets, are removed, as they can trigger immune reactions. The patent names pigs, cows, goats, sheep and humans as possible donors. The amount of plasma needed to produce a single concentrated dose is at least as much as the recipient has in their entire body, it states. If the therapy ever shows promise in humans -- large trials are needed in more animals first -- Katcher believes the plasma could be collected from pigs at abbatoirs.

SpaceX on Thursday test fired 31 of the 33 engines in the towering rocket booster of its Starship prototype, as the company prepares to launch the rocket to orbit for the first time. CNBC reports: Called a "static fire," the milestone test is the final major hurdle before SpaceX tries to launch the nearly 400-foot-tall rocket to space. The company said in a tweet shortly after the test that the engines at the base of the Super Heavy booster fired for "full duration," meaning the expected length of the test. CEO Elon Musk said in a subsequent tweet that SpaceX turned off one engine before the test and another engine "stopped itself." "Still enough engines to reach orbit!" Musk said.

SpaceX has steadily been building up to the first flight test of its Starship rocket. President and COO Gwynne Shotwell on Wednesday stressed the first launch attempt would be experimental. The company will next analyze the result of Thursday's static fire test. Shotwell estimated that a successful static would see SpaceX ready to launch the first Starship orbital flight "within the next month or so." You can watch the static fire test here.

Chip suppliers have warned that a European effort to impose a ban on "forever chemicals" will cause widespread disruption to already tight semiconductor supply chains. From a report: Five European countries, including Germany and the Netherlands, on Tuesday proposed that the EU phase out tens of thousands of so-called forever chemicals, known as PFAS, used in the production of semiconductors, batteries, aircraft, cars, medical equipment and even frying pans and ski wax.

The ban would constitute "the broadest restriction proposal in history," Frauke Averbeck, who led the proposal for the German Environment Agency, said. "It's a huge step for us to take." Richard Luit, senior policy adviser at the Dutch National Institute for Public Health and Environment, added: "If no action is taken we estimate that the societal costs will exceed the costs without a restriction." However, industry executives warned that a broad ban could have severe consequences for many sectors. Chemours, a leading supplier of high-end fluoropolymers, warned that the chemicals were "absolutely critical" for semiconductor manufacturing as well as a wide range of other industries.

Scientists have spotted 12 more moons around Jupiter, adding to an already-huge number that just seems to grow and grow. From a report: There's so many moons around this gas giant planet that astronomer Scott Sheppard struggles to keep track. "With this new haul, we're up to, I believe, 92 ... actually, I have to check that," he says, leaning over to type into his computer at the Carnegie Institution for Science, Earth and Planets Laboratory in Washington, DC. " Yeah, so 92 is the number that we have right now." His team is currently tracking some more moons that, once confirmed over the next year or two, should put Jupiter over 100.

There's good reason to keep looking for more moons, Sheppard says: If one was found in a convenient orbit, a spacecraft on a mission to Jupiter could fly close by and take a peek, letting scientists figure out what the moonlet is made of. That's important because Jupiter's small, outer moons are fairly mysterious. Astronomers suspect that they are remnants of the original building material that got used to form the solar system's biggest planet. Sheppard has been discovering new moons around Jupiter for over two decades, leading some colleagues to jokingly call him "Galileo," after the famous astronomer who first discovered that Jupiter had moons in 1610. Every few years, Sheppard and his fellow astronomers take advantage of better technology and bigger telescopes to add more moons to the tally. At the moment, Jupiter holds the record for the most known moons, beating out Saturn, which has 83.

In a study published Wednesday in PLOS Climate, a group of astrophysicists proposes shooting lunar dust into space to help partially shield sunlight to Earth. The Washington Post reports: The team used computer simulations to model various scenarios where massive quantities of dust (and we mean a lot of dust) in space can reduce the amount of Earthbound sunlight by 1 to 2 percent, or up to about six days of an obscured sun in a year. Their cheapest and most efficient idea is to launch dust from the moon, which would land into orbit between the sun and Earth and create a sunshade. Yes, the idea sounds like science fiction. Yes, it would require (a lot of) new engineering. Yes, there are more feasible climate mitigation tactics that can be employed now and in the near future. But the researchers view this rigorous physics experiment as a backup option that could aid -- not replace -- existing strategies to help humankind live on a more comfortable Earth. [...]

In the new study, the authors concede their idea isn't perfect but say it addresses some problems with previous concepts. For instance, the amount of material needed to actually shade the sun exceeds 10 billion kilograms (22 billion pounds), which is about 100 times more mass than humans have ever sent into space. Bromley says dust is very efficient at scattering sunlight relative to its size. The team considered different types of dust, scattering properties and size. The team found that aggregates of fluffy and highly porous particles scattered light the best, but they opted for a particle perhaps more easily accessible in space: moon dust. "We really do focus on lunar dust, just plain old, as-it-is lunar dust, without any indication of changing its shape," said Bromley, who said future moon mining could excavate the dust needed. Perhaps the greatest challenge is getting the right material exactly where you need it, Bromley said.

In one computer simulation, the team shot lunar dust from the moon's surface toward the sun. Bromley said the device to launch the lunar dust into space could be something similar to an electromagnetic gun, cannon or rocket -- picture a T-shirt cannon sending dust into orbit. In the simulation, the dust scattered along various routes until the team found suitable trajectories, which allowed the dust to concentrate temporarily and act as a sun shield. Bromley said the dust would periodically disperse away from Earth and throughout the solar system. In another simulation, the team shot off dust from a space platform about 1 million miles from Earth. This would be in an area known as L1 (Lagrange point 1), where objects tend to stay put because of equal gravitational pulls between the sun and Earth. This idea required more astronomical cost and effort because they would need a space platform and a dust supply that could be easily replenished. In either scenario, people on the ground wouldn't be able to see the shield or feel any difference, although some tools would probably be able to detect changes in the incoming solar radiation.

An anonymous reader quotes a report from Bloomberg: When Nestle SA's peanut allergy medicine first hit the market in 2020, Robert Wood, the director of pediatric allergy at Johns Hopkins Hospital in Baltimore, started preparing to offer it to the children he treats. But Covid-19 soon derailed in-person treatment, so over the next year and a half Wood and his colleagues told some 1,000 patients about the new drug instead, suggesting they consider it when the pandemic abated. Their responses came as a shock. Only six people were interested in a medicine that had been billed as a game changer for life-threatening allergies -- the first of its kind to be cleared by US authorities. Three years later, Wood has yet to prescribe the drug, Palforzia, and he isn't alone. Doctors and patients from California to Germany appear to be shunning the medicine in favor of the tried-and-true prescription for sufferers: simply avoiding peanuts and carrying an adrenaline injection for emergencies.

Nestle's chief executive officer, Mark Schneider, admitted as much in November, conceding that the drug's uptake had been slow. Schneider in 2020 bought out Palforzia's developer for $2.6 billion, paying a staggering 174% premium as he sought to take "the science business to the next level," snapping up vitamin makers such as Puritan's Pride and Solgar as well. The company is looking for a buyer, and the Swiss food giant says it will have to recognize a significant impairment to the deal's original value -- likely presaging a big writedown at a time when its core grocery business faces pressure from inflation. Maybe the company known for Nespresso capsules and Kit Kat chocolate wafers was never the right owner for a complex-to-administer niche medicine, but Schneider is on the hunt to find new avenues of growth in keeping with his strategic tilt toward health and wellness. The CEO "is looking to make acquisitions in new areas, and that inherently carries risks," says Martin Deboo, an analyst at Jefferies. "Palforzia is a signal of that." Nestle reiterated its commitment to nutritional health in an email and said Palforzia is safe and effective and solves the problem of variable potency that can hobble efficacy or trigger an allergic reaction with other less stringent treatments.

The product is essentially peanut protein that's been packed in a pill, standardized and categorized as a medicine after meeting the Food and Drug Administration's exacting clinical-trial requirements on safety and efficacy. By exposing children to tiny but gradually increasing amounts of the ingredient, Palforzia slowly raises their sensitivity threshold. But the process requires commitment by parents and kids to a demanding regime that lasts more than a year. [...] Palforzia is not without risk. During the clinical trials, about 9% of children suffered potentially dangerous immune reactions when their doses were being increased. [...] Bloomberg notes that Germany's Institute for Quality and Efficiency in Health Care concluded that Nestle's drug "doesn't offer any advantage over peanut avoidance." A UK panel that assess medicines' cost-effectiveness also found the drug to be quite expensive, costing about $6,220 per patient in England.

"As for Wood at Johns Hopkins, he says the allergy center would've lost money administering Palforzia -- something it was willing to do if there had been enough interest among patients. When asked whether some patients might've gone elsewhere for Palforzia, Wood says probably not."

"Man goes to the doctor for a sleep apnea diagnosis, a few months later he gets a letter from the state of Maryland about his sleep apnea -- and they won't tell him how they found out about it," writes Slashdot reader schwit1. NBC4 Washington reports: Dr. David Allick, a dentist in Rockville, was diagnosed with mild sleep apnea in June 2022. Months later, he received a letter from the MVA requesting additional information about his diagnosis in order "to determine your fitness to drive." The September 2022 letter noted failure to return the required forms, which included a report from his physician, could result in the suspension of his license. Allick said he isn't clear how the state learned about his medical diagnosis. But more importantly, he said he was previously unaware of a little-known Maryland law requiring people to report their sleep apnea diagnosis to state driving authorities. Allick said he still has questions about what prompted the ordeal. "Everybody I talked to -- nobody's heard of anything like this," he said, also acknowledging: "I'm sure they want to keep the roads safe." schwit1 adds: "How is this not a HIPAA violation?"

The investigation team at NBC4 Washington found that Allick is one of 1,310 people whose sleep apnea diagnoses "have led to medical reviews by the Maryland MVA." The state department didn't have data on how many of these Maryland drivers have had their license suspended.

Pollution from livestock farming, pharmaceuticals and healthcare is threatening to destroy a key pillar of modern medicine, as spills of manure and other pollution into waterways are adding to the global rise of superbugs, the UN has warned. From a report: Animal farming is one of the key sources of strains of bacteria that have developed resistance to all forms of antibiotics, through the overuse of the medicines in farming. Pharmaceutical pollution of waterways, from drug manufacturing plants, is also a major contributor, along with the failure to provide sanitation and control sewage around the world, and to tackle waste from healthcare facilities. Resistant superbugs can survive in untreated sewage.

The findings of the new report, published on Tuesday, show that pollution and a lack of sanitation in the developing world can no longer be regarded by the rich world as a faraway and localised problem for poor people. When superbugs emerge, they quickly spread, and threaten the health even of people in well-funded healthcare systems in the rich world. Poor sanitation and healthcare, and a lack of regulation in animal farming, create breeding grounds for resistant bacteria, and threaten global health as a result, the UN Environment Programme found in the report. As many as 10 million people a year could be dying by 2050 as a result of antimicrobial resistance (AMR), according to the UN, making it as big a killer as cancer is today. The rise of superbugs will also take an economic toll, resulting in the loss of about $3.4tn a year by the end of this decade, and pushing 24 million people into extreme poverty.

When shaken and chilled to minus 320 degrees Fahrenheit, ordinary frozen water "turns into something different," reports the New York Times, "a newly discovered form of ice made of a jumble of molecules with unique properties." The ice of our everyday lives consists of water molecules lined up in a hexagonal pattern, and those hexagonal lattices neatly stack on top of each other.... With permutations of temperature and pressure outside what generally occurs on Earth, water molecules can be pushed into other crystal structures.

"This is completely unexpected and very surprising," said Christoph Salzmann, a chemistry professor at University College London in England and an author of a paper published on Thursday in the journal Science that described the ice.... The new discovery shows, once again, that water, a molecule without which life is not known to be able to exist, is still hiding scientific surprises yet to be revealed. This experiment employed relatively simple, inexpensive equipment to reveal a form of ice that could exist elsewhere in the solar system and throughout the universe.
And according to LiveScience, the new form of ice has some unusual properties: Among them, Salzmann said, is that when the researchers compressed the medium-density ice and heated it to minus 185 F (minus 120 C), the ice recrystallized, releasing a large amount of heat. "With other forms of [amorphous] ice, if you compress them and you release the pressure, it's like nothing happened," Salzmann said. "But the MDA [medium-density amorphous ice] somehow has this ability to store the mechanical energy and release it through heating."

Medium-density amorphous ice might occur naturally on the ice moons of gas giant planets, Salzmann said, where the gravitational forces of the enormous worlds compress and shear the moons' ice. If so, the mechanical energy stored in this form of ice could influence the tectonics on these Hoth-like moons....

Scientists still debate the nature of water at extremely low temperatures. Any debate now needs to take into account medium-density amorphous ice, Salzmann said.
Thanks to long-time Slashdot reader fahrbot-bot for submitting the article.

Blobs of human brain tissue have been transplanted into the brains of rats in work that could pave the way for new treatments for devastating brain injuries. The Guardian reports: The groundbreaking study showed that the "human brain organoids" -- sesame seed-sized balls of neurons -- were able to integrate into the rat brain, linking up with their blood supplies and communicating with the rat neurons. The team behind the work suggest that eventually doctors might be able to grow blobs of brain tissue from a patient's own cells in the lab and use them to repair brain injuries caused by stroke or trauma.

Chen and colleagues grew human brain organoids in a dish until they were about 1.5mm in diameter. The balls of tissue were then transplanted into the brains of adult rats that had sustained injuries to their visual cortex. Within three months, the grafted organoids had integrated with their host's brain, hooking up with the blood supply, expanding to several times the initial volume and sending out projections that linked up with the rat's neurons, according to the study published in Cell Stem Cell. The scientists did not assess whether the implants improved how well the rats were able to function, but tests showed that the human neurons fired off electrical signals when the rats were exposed to flashing lights.

An anonymous reader quotes a report from The Guardian: After decades of "demonization", psychiatrists will be able to prescribe MDMA and psilocybin in Australia from July this year. The Therapeutic Goods Administration made the surprise announcement on Friday afternoon. The drugs will only be allowed to be used in a very limited way, and remain otherwise prohibited, but the move was described as a "very welcome step away from what has been decades of demonization" by Dr David Caldicott, a clinical senior lecturer in emergency medicine at Australian National University.

3,4-methylenedioxy-methamphetamine (MDMA) is commonly known as ecstasy, while psilocybin is a psychedelic commonly found in so-called magic mushrooms. Both drugs were used experimentally and therapeutically decades ago, before being criminalized. Specifically authorized psychiatrists will be able to prescribe MDMA for post-traumatic stress disorder, and psilocybin for treatment-resistant depression. Caldicott said it had become "abundantly clear" that a controlled supply of both MDMA and psilocybin "can have dramatic effects on conditions often considered refractory to contemporary treatment" and would particularly benefit returned service men and women from the Australian defense force. "The safe 're-medicalization' of certain historically illicit drugs is a very welcome step away from what has been decades of demonization," he said.

"In addition to a clear and evolving therapeutic benefit, it also offers the chance to catch up on the decades of lost opportunity [of] delving into the inner workings of the human mind, abandoned for so long as part of an ill-conceived, ideological "war on drugs.'"

As global demand for Covid-19 vaccines dries up, the program responsible for vaccinating the world's poor has been urgently negotiating to try to get out of its deals with pharmaceutical companies for shots it no longer needs. From a report: Drug companies have so far declined to refund $1.4 billion in advance payments for now-canceled doses, according to confidential documents obtained by The New York Times. Gavi, the international immunization organization that bought the shots on behalf of the global Covid vaccination program, Covax, has said little publicly about the costs of canceling the orders. But Gavi financial documents show the organization has been trying to stanch the financial damage. If it cannot strike a more favorable agreement with another company, Johnson & Johnson, it could have to pay still more.

Gavi is a Geneva-based nongovernmental organization that uses funds from donors including the U.S. government and the Bill and Melinda Gates Foundation to provide childhood immunizations to lower-income nations. Early in the pandemic, it was charged with buying Covid vaccinations for the developing world -- armed with one of the largest-ever mobilizations of humanitarian funding -- and began negotiations with the vaccine makers. Those negotiations went badly at the outset. The companies initially shut the organization out of the market, prioritizing high-income countries that were able to pay more to lock up the first doses. [...] The vaccine makers have brought in more than $13 billion from the shots that have been distributed through Covax. Under the contracts, the companies are not obligated to return the prepayments Gavi gave them to reserve vaccines that were ultimately canceled.

Chess experts make more mistakes when air pollution is high, a study has found. From a report: Experts used computer models to analyse the quality of games played and found that with a modest increase in fine particulate matter, the probability that chess players would make an error increased by 2.1 percentage points, and the magnitude of those errors increased by 10.8%. The paper, published in the journal Management Science, studied the performance of 121 chess players in three seven-round tournaments in Germany in 2017, 2018, and 2019, comprising more than 30,000 chess moves.

The researchers compared the actual moves the players made against the optimal moves determined by the powerful chess engine Stockfish. In the tournament venues, the researchers attached three web-connected air quality sensors to measure carbon dioxide, PM2.5 concentrations, and temperature. Each tournament lasted eight weeks, meaning players faced a variety of air conditions. Fine particulate matter, or PM2.5, refers to tiny particles 2.5 microns or less in diameter, which are often expelled by burning matter such as that from car engines, coal plants, forest fires, and wood burners. Further reading: Study Reveals Links Between UK Air Pollution and Mental Ill-Health.

Planting more trees could mean fewer people die from increasingly high summer temperatures in cities, a study suggests. The Guardian reports: Increasing the level of tree cover from the European average of 14.9% to 30% can lower the temperature in cities by 0.4C, which could reduce heat-related deaths by 39.5%, according to first-of-its-kind modeling of 93 European cities by an international team of researchers. [...] The researchers used mortality data to estimate the potential reduction in deaths from lower temperatures as a result of increased tree coverage. Using data from 2015 they estimated that out of the 6,700 premature deaths that year attributed to higher urban temperatures, 2,644 could have been prevented had tree cover been increased.

The cities most likely to benefit from the increase in tree coverage are in south and eastern Europe, where summer temperatures are highest and tree coverage tends to be lower. In Cluj-Napoca in Romania -- which had the highest number of premature deaths due to heat in 2015, at 32 per 100,000 people -- tree coverage is just 7%. In Lisbon, Portugal it is as low as 3.6% and in Barcelona its 8.4%. That compares with 15.5% in London and 34% in Oslo. Study co-author Mark Nieuwenhuijsen, a researcher at the Barcelona Institute for Global Health, said the team picked 30% as that is a target that many cities are currently working towards.

He said there was no need for buildings to be razed and replaced with parks, since there is enough space to plant more trees in all the cities the team looked at. He praised initiatives such as the EU's 3 billion trees plan, and the UK government's proposal to ensure every home is within a 15-minute walk from green space, though he noted that policymakers must ensure trees are evenly distributed between richer and poor neighborhoods. He added that cities which are "too car-dominated" should consider replacing asphalt roads, which absorb heat, with trees. Planting more trees in cities should be prioritized because it brings a huge range of health benefits beyond reducing heat-related deaths, he added, including reducing cardiovascular disease, dementia and poor mental health. The study has been published in the journal The Lancet.

An anonymous reader quotes a report from Wired: Your gut has an obvious job: It processes the food you eat. But it has another important function: It protects you from the bacteria, viruses, or allergens you ingest along with that food. "The largest part of the immune system in humans is the GI tract, and our biggest exposure to the world is what we put in our mouth," says Michael Helmrath, a pediatric surgeon at Cincinnati Children's Hospital Medical Center who treats patients with intestinal diseases. Sometimes this system malfunctions or doesn't develop properly, which can lead to gastrointestinal conditions like ulcerative colitis, Crohn's disease, and celiac -- all of which are on the rise worldwide. Studying these conditions in animals can only tell us so much, since their diets and immune systems are very different from ours.

In search of a better method, last week Helmrath and his colleagues announced in the journal Nature Biotechnology that they had transplanted tiny, three-dimensional balls of human intestinal tissue into mice. After several weeks, these spheres -- known as organoids -- developed key features of the human immune system. The model could be used to mimic the human intestinal system without having to experiment on sick patients. The experiment is a dramatic follow-up from 2010, when researchers at Cincinnati Children's became the first in the world to create a working intestine organoid -- but their initial model was a simpler version in a lab dish. A few years later, Helmrath says, they realized "we needed it to become more like human tissue." [...]

Matthew Grisham, a gastroenterologist at Texas Tech University Health Sciences Center who wasn't involved in the new study, says the findings are exciting because these structures have a "human immune cell composition very similar to that of the developing human gut." He says the organoid model will help researchers investigate the mechanisms responsible for intestinal infection, inflammation, and food allergies. The Cincinnati researchers also hope their organoids could one day be used to treat people born with genetic defects that affect their digestive systems, or those who have lost intestinal function to cancer or inflammatory bowel diseases. That these organoids can flourish in a mouse is an encouraging sign that they might be able to grow on their own if transplanted into a person. Using induced pluripotent stem cells taken from patients, scientists could perhaps one day make customized tissue patches to help heal damaged organs. In the near-term, Helmrath says his team plans on making organoids from patients' own cells to test out possible individualized therapies. "This is right around the corner," he says.

One of the most precise surveys of the structure of the universe has suggested it is "less clumpy" than expected, in findings that could indicate the existence of mysterious forces at work. From a report: The observations by the Dark Energy Survey and the South Pole Telescope chart the distribution of matter with the aim of understanding the competing forces that shaped the evolution of the universe and govern its ultimate fate. The extraordinarily detailed analysis adds to a body of evidence that suggests there may be a crucial component missing from the so-called standard model of physics.

"It seems like there is slightly less [clumpiness] in the current universe than we would predict assuming our standard cosmological model anchored to the early universe," said Eric Baxter, an astrophysicist at the University of Hawaii and co-author of the study. The results did not pass the statistical threshold that scientists consider to be ironclad enough to claim a discovery, but they do come after similar findings from previous surveys that hint a crack could be opening up between theoretical predictions and what is actually going on in the universe. "If the finding stands up it's very exciting," said Dr Chihway Chang, an astrophysicist at the University of Chicago and a lead author. "The whole point of physics is to test models and break them. The best scenario is it helps us understand more about the nature of dark matter and dark energy."

Physicists at MIT have for the very first time observed a resonance between two colliding ultracold molecules. The findings have been published in the journal Nature. From the report: They found that a cloud of super-cooled sodium-lithium (NaLi) molecules disappeared 100 times faster than normal when exposed to a very specific magnetic field. The molecules' rapid disappearance is a sign that the magnetic field tuned the particles into a resonance, driving them to react more quickly than they normally would. The findings shed light on the mysterious forces that drive molecules to chemically react. They also suggest that scientists could one day harness particles' natural resonances to steer and control certain chemical reactions.

Overall, the discovery provides a deeper understanding of molecular dynamics and chemistry. While the team does not anticipate scientists being able to stimulate resonance, and steer reactions, at the level of organic chemistry, it could one day be possible to do so at the quantum scale. "One of the main themes of quantum science is studying systems of increasing complexity, especially when quantum control is potentially in the offing," says John Doyle, professor of physics at Harvard University, who was not involved in the group's research. "These kind of resonances, first seen in simple atoms and then more complicated ones, led to amazing advances in atomic physics. Now that this is seen in molecules, we should first understand it in detail, and then let the imagination wander and think what it might be good for, perhaps constructing larger ultracold molecules, perhaps studying interesting states of matter."

An anonymous reader quotes a report from Gizmodo: Genetic engineering company Colossal Biosciences said Tuesday that it will try to resurrect the extinct dodo bird, and it's received $150 million in new funding to support its "de-extinction" activities. The dodo was already part of Colossal's plans by September 2022, but now the company has announced it with all the pomp, circumstance, and seed funding that suggests it will actually go after that goal. The $150 million, the company's second round of funding, was led by several venture capital firms, including United States Innovative Technology Fund and In-Q-Tel, a VC firm funded by the CIA that first put money into the company in September. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial. Adding the dodo to its official docket brings Colossal's total de-extinction targets to three: the woolly mammoth (the company's first target species, announced in September 2021), and the thylacine, a.k.a. the Tasmanian tiger, the largest carnivorous marsupial.

Colossal's stated goal is not to simply bring these creatures back for vibes; its contention is that reintroducing the species to their respective habitats would help restore a certain amount of normalcy to those environments. Mammoths died out about 4,000 years ago on Wrangel Island, off the northeastern coast of Russia. The dodo, a species of flightless bird native to the island of Mauritius, was gone by 1681. The last known thylacine died at a zoo in Tasmania in 1936. Scientists have sequenced the genomes of all three species -- the mammoth's in 2015, the dodo's in 2016, and the thylacine's in 2018. The latter species were driven to extinction by humankind; humans hunted the dodo, introduced predators and pests to its environment, and contributed to its habitat loss. Humans may have played a role in mammoth extinction as well, but the dodo and the thylacine are classic examples of our ability to wipe out species at extraordinary speed. [...]

If the company's work pans out -- and that's a big if -- proxy species of those extinct animals will be brought to bear. That's because the genetically engineered animals produced by Colossal would not be a bonafide mammoth, dodo, or thylacine. In 2016, the International Union for Conservation of Nature's Species Survival Commission published a report (PDF) denoting ground rules for creating proxy species. "Proxy is used here to mean a substitute that would represent in some sense (e.g. phenotypically, behaviorally, ecologically) another entity -- the extinct form," the commission stated, adding that "Proxy is preferred to facsimile, which implies creation of an exact copy." De-extinction is something of a misnomer, as this process, if successful, will yield science's best analogue for an extinct creature, not the creature itself as it existed in the past. De-extinction methods generally rely on using a living creature's genetics in the resurrection process. That means any 21st-century mammoth will have at least some modern elephant DNA imbued in it, and any nascent thylacine would be produced from the genome and egg of a related species.

schwit1 shares a report from Ars Technica: More than four months have passed since the launch of Blue Origin's New Shepard rocket ended in failure. No humans were onboard the vehicle because it was conducting a suborbital scientific research mission, but the failure has grounded the New Shepard fleet ever since. The rocket's single main engine failed about one minute into the flight, at an altitude of around 9 km, as it was throttling back up after passing through the period of maximum dynamic pressure. At that point a large fire erupted in the BE-3 engine, and the New Shepard capsule's solid rocket motor-powered escape system fired as intended, pulling the capsule away from the exploding rocket. The capsule experienced high G-forces during this return but appeared to make a safe landing.

Three days after this accident with the New Shepard-23 mission, the bipartisan leadership of the House Subcommittee on Space and Aeronautics sent a letter to the Federal Aviation Administration, calling for a thorough investigation. In an interview with Ars later that month, the chair of the subcommittee, US Rep. Don Beyer (D-Va.), urged Blue Origin to be transparent. "I'm heavily in favor of transparency, and I'm hoping that the FAA comes through pretty quickly with this," Beyer said. "I would strongly encourage Blue Origin to be as transparent as possible, because that builds trust. It doesn't have to be overnight, but it would be nice to keep people updated on the progress they're making." The company has not heeded this advice. An application filed with the FCC last week suggests Blue Origin might target a launch for its next New Shepard flight between April 1 and June 1. However, a spokesperson downplayed that speculation, saying it is not tied to a specific launch. "As a matter of course, we submit rolling FCC license requests to ensure we have continuous coverage for launches," the spokesperson said.

It's also unclear whether this next launch will be an uncrewed or a crewed mission.

Slashdot reader schwit1 adds: "For the time being, the New Space Race is pretty much Elon vs the World."